Pleiotropic effects of statins: new therapeutic targets in drug design

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 389, Issue 7, 2016, Pages 695-712

  Bedi, Onkar ^b   Dhawan, Veena ^b   Sharma, P L ^b   Kumar, Puneet ^a  

^a ISF COLLEGE OF PHARMACY   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Anti inflammatory; Atherosclerotic; Pleiotropic effects; Rheumatoid arthritis; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; RHO KINASE; ADENOSINE RECEPTOR STIMULATING AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CARDIOVASCULAR AGENT; IMMUNOLOGIC FACTOR; LIPID; PROTEIN KINASE INHIBITOR; RAC1 PROTEIN;

ANTICOAGULATION; ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ATHEROGENESIS; CARDIORENAL SYNDROME; CARDIOVASCULAR DISEASE; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HUMAN; IMMUNOMODULATION; NEUROPROTECTION; NONHUMAN; OVARY POLYCYSTIC DISEASE; PLEIOTROPY; REVIEW; VASCULAR REMODELING; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG EFFECTS; DYSLIPIDEMIAS; HISTORY; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CARDIOVASCULAR AGENTS; DRUG DESIGN; DYSLIPIDEMIAS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOLOGIC FACTORS; LIPIDS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PROTEIN KINASE INHIBITORS; PURINERGIC P1 RECEPTOR AGONISTS; RAC1 GTP-BINDING PROTEIN; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION;

EID: 84966290897     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-016-1252-4     Document Type: Review

References (167)

1. Abe M, Toyohara T, Ishii A, Suzuki T, Noguchi N, Akiyama Y, Shiwaku HO, Nakagomi-Hagihara R, Zheng G, Shibata E (2010) The HMG-CoA reductase inhibitor pravastatin stimulates insulin secretion through organic anion transporter polypeptides. Drug Metab Pharmacokinet 25(3):74–282
2. Alanazi F (2010) Pravastatin provides antioxidant activity and protection of erythrocytes loaded primaquine. Int J Med Sci 7(6):358
3. Alarcon J, Aguila S, Arancibia-Avila P, Fuentes O, Zamorano-Ponce E, Hernández M (2003) Production and purification of statins from Pleurotus ostreatus (Basidiomycetes) strains. Zeitschrift für Naturforschung C 58(1-2):62–64
4. Albert MA, Danielson E, Rifai N, Ridker PM, Investigators P (2001) Effect of statin therapy on C-reactive protein levels, the pravastatin inflammation/CRP evaluation (PRINCE), a randomized trial and cohort study. JAMA 286(1):64–70
5. Albert MA, Glynn RJ, Ridker PM (2003) Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation 108(2):161–165
6. Altschul R, Hoffer A, Stephen J (1995) Influence of nicotinic acid on serum cholesterol in man. Arch Biochem Biophys 54(2):558–559
7. Avigan J, Steinberg D, Thompson MJ, Mosettig E (1905) Mechanism of action of MER-29, an inhibitor of cholesterol biosynthesis. Biochem Biophys Res Commun 2(1):63–65
8. Baigent C, Landray MJ, Reith C, et al. (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection), a randomised placebo-controlled trial. Lancet 377:2181–2192
9. Banaszewska B, Pawelczyk L, Spaczynski RZ, Dziura J, Duleba AJ (2007) Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome, prospective, randomized, crossover trial. J Clin Endocrinol Metab 92(2):456–461
10. Bar-On P, Crews L, Koob AO, Mizuno H, Adame A, Spencer B, Masliah E (2008) Statins reduce neuronal α-synuclein aggregation in in vitro models of Parkinson’s disease. J Neurochem 105(5):1656–1667
11. Bianchi, Stefano, Daniela Grimaldi and Roberto Bigazzi (2011) Statins and lipid-lowering strategies in cardiorenal patients 143-150
12. Björnsson E, Jacobsen EI, Kalaitzakis E (2011) Hepatotoxicity associated with statin, reports of idiosyncratic liver injury post-marketing. J Hepatol 56(2):374–380
13. Blanco-Colio LM, Tuñón J, Martín-Ventura JL, Egido J (2003) Anti-inflammatory and immunomodulatory effects of statins. Kidney Int 63(1):12–23
14. Blanquart C, Mansouri R, Paumelle R, Fruchart JC, Staels B, Glineur C (2004) The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor α. Mol Endocrinol 18(8):1906–1918
15. Bloch K (1964) Speech at the Nobel Banquet in Stockholm, December 10, 1964
16. Bloch K (1965) The biological synthesis of cholesterol. Science 150:19–28
17. Blohm TR, Mac Kenzie RD (1959) Specific inhibition of cholesterol biosynthesis by a synthetic compound (MER-29). Arch Biochem Biophys 85(1):245–249
18. Bonfrate L, Procino G, Wang DQ, Svelto M, Portincasa P (2015) A novel therapeutic effect of statin on nephrogenic diabetes insipidus. J Cell Mol Med 19(2):265–282
19. Brown JH, Del Re DP, Sussman MA (2006) The Rac and Rho hall of fame a decade of hypertrophic signaling hits. Circ Res 98(6):730–742
20. Brown MS, Goldstein JL (1986) A receptor-mediated pathway for cholesterol homeostasis. Science 232(4746):34–47
21. Burridge K, Wennerberg K (2004) Rho and Rac take center stage. Cell 116(2):167–179
22. Cannon Christopher P, Michael A, Blazing Robert P, Giugliano AMC, Jennifer A, Theroux WP, Darius H, et al. (2015) Ezetimibe added to statin therapy after acute coronary syndromes. New Engl J Med 25:2387–2397
23. Carmina E, Lobo RA (1999) Polycystic ovary syndrome (PCOS), arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 84(6):1897–1899
24. Chan SY, Mancini GJ, Ignaszewski A, Frohlich J (2008) Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio, a randomized crossover study. BMC Pharmacol Toxicol 8(1):10
25. Cipollone F, Fazia M, Iezzi A, et al. (2003) Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation 107(11):1479–1485
26. Cornforth JW, Popják G (1958) Biosynthesis of cholesterol. Br Med Bull 14:221–226
27. Corsini A, Bellosta S, Baetta R, Fumagalli R, Bernini F (1999) New insights into the pharmacodynamics and pharmacokinetic properties of statin. Pharmacol Ther 84:413–428
28. Corti R, Osende JI, Fallon JT, Fuster V, Mizsei G, Jneid H, Wright SD, Chaplin WF, Badimon JJ (2004) The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging. J Am Coll Cardiol 43(3):464–473
29. Cramer C, Haan M, Galea S, Langa K, Kalbfleisch J (2008) Use of statin and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 71(5):344–350
30. Cunard R, Eto Y, Muljadi JT, Glass CK, Kelly CJ, Ricote M (2004) Repression of IFN-gamma expression by peroxisome proliferator-activated receptor gamma. J Immunol 172:7530–7536
31. Cuthbert J, Lipsky P (1981) Sterol metabolism and lymphocyte responsiveness, inhibition of endogenous sterol synthesis prevents mitogen-induced human T cell proliferation. J Immunol 126(6):2093–2099
32. Cutts JL, Bankhurst A (1989) Suppression of lymphoid cell function in vitro by inhibition of 3-hydroxy-3-methylglutaryl coenzyme a reductase by lovastatin. Int J Immunopharmacol 11(8):863–869
33. Danesh FR, Sadeghi MM, Amro N, Philips C, Zeng L, Lin S, Sahai A, Kanwar YS (2002) 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway, implications for diabetic nephropathy. Proc Natl Acad Sci 99(12):8301–8305
34. Davis T, Yeap B, Davis W, Bruce D (2008) Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes, the Fremantle Diabetes Study. Diabetologia 51(4):562–566
35. Deakin S, Leviev I, Guernier S, et al. (2003) Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. ArterosclerThromb Vasc Biol 23:2083–2089
36. Drel LF, VR Szabó C, Stevens MJ, Obrosova IG (2005) Low-dose poly (ADP-ribose) polymerase inhibitor-containing combination therapies reverse early peripheral diabetic neuropathy. Diabetes 54(5):1514–1522
37. Devane GW, Czekala N, Judd HL, Yen SS (1975) Circulating gonadotropins, estrogens, and androgens in polycystic ovarian disease. Am J Obstet Gynecol 121
38. Dobs AS, Schrott H, Davidson MH, Bays H, Stein EA, Kush D, Wu M, Mitchel Y, Illingworth RD (2000) Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metabolism 49(9):1234–1238
39. Du H, Hu H, Zheng H, Hao J, Yang J, Cui W (2014) Effects of peroxisome proliferator-activated receptor γ in simvastatin antiplatelet activity: influences on cAMP and mitogen-activated protein kinases. Thromb Res 134(1):111–120
40. DuBroff R, De Lorgeril M (2015) Cholesterol confusion and statin controversy. World J Cardiol 7(7):404
41. Duleba AJ, Banaszewska B, Spaczynski RZ, Pawelczyk L (2006) Simvastatin improves biochemical parameters in women with polycystic ovary syndrome, results of a prospective, randomized trial. Fertil Steril 85(4):996–1001
42. Ebrahim S, Taylor FC, Brindle P (2014) Statins for the primary prevention of cardiovascular disease. BMJ 348
43. Emilia M, Carmona-Rodríguez L, Tardáguila M, Azcoitia I, González-Martín A, Almonacid L, Casas J, Fabriás G, Mañes S (2013) A lovastatin-elicited genetic program inhibits M2 macrophage polarization and enhances T cell infiltration into spontaneous mouse mammary tumors. Oncotarget 4(12):2288
44. Endo A, Kuroda M (1976) Citrinin, an inhibitor of cholesterol synthesis. J Antibiot 8:841
45. Endo A (2008) A gift from nature, the birth of the statins. Nat Med 14(10):1050–1052
46. Endo A, Kuroda M, Tsujita Y (1976) ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum. J Antibiot 29:1346–1348
47. Endo A, Tsujita T, Kuroda M, Tanzawa K (1977) Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutarylcoenzyme A reductase. Eur J Biochem 77:31–36
48. Ersoy A, Koc ER, Sahin S, Duzgun U, Acar B, Ilhan A (2014) Possible effects of rosuvastatin on noise-induced oxidative stress in rat brain. Noise Health 16(68):18
49. Eslami L, Merat S, Malekzadeh R Nasseri-Moghaddam S & Aramin H (2013) Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. The Cochrane Library
50. Everett BM, Mora S, Glynn RJ, MacFadyen J, Ridker PM (2014) Safety profile of subjects treated to very low low-density lipoprotein cholesterol levels (<30 mg/dl) with rosuvastatin 20 mg daily (from JUPITER). Am J Cardiol 1114(11):1682–1689
51. Ferrari D, Vitiello L, Idzko M, la Sala A (2015) Purinergic signaling in atherosclerosis. Trends Mol Med 21(3):184–192
52. Gofman JW (1956) Serum lipoproteins and the evaluation of atherosclerosis. Ann N Y Acad Sci 64(4):590–595
53. Gofman JW, Lindgren FT, Elliott H (1949) Ultracentrifugal studies of lipoproteins of human serum. J Biol Chem 179(2):973–979
54. Goldstein J, Brown MS (2003) Cholesterol, a century of research Howard Hughes. Med Inst Bull 16(3)
55. Gregg D, Rauscher FM, Goldschmidt-Clermont PJ (2003) Rac regulates cardiovascular superoxide through diverse molecular interactions, more than a binary GTP switch. Am J Phys Cell Physiol 285(4):C723–C734
56. Grundy SM, Cleeman JI, BaireyMerz NC, et al. (2004) Implications of recent clinical trials for the NCEP adult treatment panel III guidelines. J Am Coll Cardiol 44:720–722
57. Hall A (1998) G proteins and small GTPases, distant relatives keep in touch. Science 280(5372):2074–2075
58. Hamelin BA, Turgeon J (1998) Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 19(1):26–37
59. Heeba G, Moselhy M, Hassan M, Khalifa M, Gryglewski R, Malinski T (2004) Anti-atherogenic effect of statin s, role of nitric oxide, peroxynitrite and haem oxygenase-1. Br J Pharmacol 156(8):1256–1266
60. Hilbert T, Poth J, Frede S, Klaschik S, Hoeft A, Baumgarten G, Knuefermann P (2013) Anti-atherogenic effects of statin s, impact on angiopoietin-2 release from endothelial cells. Biochem Pharmacol 86(10):1452–1460
61. Horton JD, Goldstein JL, Brown MS (2002) SREBPs, activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109:1125–1131
62. Hsu M, Muchova L, Morioka I, Wong RJ, Schröder H, Stevenson DK (2006) Tissue-specific effects of statins on the expression of heme oxygenase-1 in vivo. Biochem Biophys Res Commun 343(3):738–744
63. Issemann I, Green S (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347(6294):645–650
64. Istvan E, Deisenhofer S, Johann (2001) Structural mechanism for statin inhibition of HMG-CoA reductase. Sci Mag 292(5519):1160–1164
65. Izquierdo D, Foyouzi N, Kwintkiewicz J, Duleba AJ (2004) Mevastatin inhibits ovarian theca-interstitial cell proliferation and steroidogenesis. Fertil Steril 82:1193–1197
66. Jeong JH, Yum KS, Chang JY, Kim M, Ahn JY, Kim S, Han MK (2015) Dose-specific effect of simvastatin on hypoxia-induced HIF-1α and BACE expression in Alzheimer’s disease cybrid cells. BMC Neurol 15(1):127
67. Jiang Y, Zhang Y, Zhang H, Zhu B, Li P, Lu C, Xu Y, Chen W, Lin N (2014) Pravastatin prevents steroid-induced osteonecrosis in rats by suppressing PPARγ expression and activating Wnt signaling pathway. Exp Biol Med 239(3):347–355
68. Jing L, Fountain SJ (2012) Fluvastatin suppresses native and recombinant human P2X4 receptor function. Purinergic Signal 8(2):311–316
69. John Simons (2003) The $10 Billion Pill Hold the fries, please Lipitor, the cholesterol-lowering drug, has become the bestselling pharmaceutical in history Here's how Pfizer did it FORTUNE Magazine (http://archivefortune.com/magazines/fortune/fortune_archive/2003/01/20/335643/index.htm)
70. Jonathan A (2003) Lovastatin and beyond, the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2:517–526
71. Kalmijn S, Feskens E, Launer L, Kromhout D (1996) Cerebrovascular disease, the apolipoprotein e4 allele, and cognitive decline in a community-based study of elderly men. Stroke 27(12):2230–2235
72. Kashani A, Phillips CO, Foody JM, et al. (2006) Risks associated with statin therapy, a systematic overview of randomized clinical trials. Circulation 114:2788–2797
73. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P (2003) High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 8(13):1560–1566
74. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Sasiela WJ, Szarek M, Ganz P, Libby P (2004) Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble. CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation 110(4):386–391
75. Klein R, Klein BE, Moss SE, Cruickshanks KJ (1994) Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med 154(19):2169–2178
76. Kojanian H, Szafran-Swietlik A, Onstead-Haas LM, Haas MJ & Mooradian AD (2014) Statins prevent dextrose-induced endoplasmic reticulum stress and oxidative stress in endothelial and HepG2 cells. Am J Ther
77. Kumar A, Sharma N, Gupta A, Kalonia H, Mishra J (2012a) Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms. Brain Res 1471:13–22
78. Kumar A, Vashist A, Kumar P, Kalonia H, Mishra J (2012b) Protective effect of HMG CoA reductase inhibitors against running wheel activity induced fatigue, anxiety like behavior, oxidative stress and mitochondrial dysfunction in mice. Pharmacol Rep 64(6):1326–1336
79. Kurakata S, Kada M, Shimada Y, Komai T, Nomoto K (1996) Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacology 34(1):51–61
80. Kwak B, Mulhaupt F, Myit S, Mach F (2000) Statin as a newly recognized type of immunomodulator. Nat Med 6(12):1399–1402
81. Lai WT, Lee KT, Chu CS, et al. (2005) Influence of withdrawal of statin treatment on proinflammatory response and fibrinolytic activity in humans, an effect independent on cholesterol elevation. Int J Cardiol 98:459–464
82. Laufs U, Kilter H, Konkol C, Wassmann S, Böhm M, Nickenig G (2002) Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovasc Res 53(4):911–920
83. Laufs U, La Fata V, Plutzky J, Liao JK (1998) Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97(12):1129–1135
84. Lazzerini PE, Capperucci C, Spreafico A, Capecchi PL, Niccolini S, Ferrata P, Frediani B, Galeazzi M, Laghi-Pasini F (2013) Rosuvastatin inhibits spontaneous and IL-1β-induced interleukin-6 production from human cultured osteoblastic cells. Joint Bone Spine 80(2):195–200
85. Lee T-S, Chang C-C, Zhu Y, Shyy JY (2004) Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection. Circulation 110(10):1296–1302
86. Lennernas H, Fager G (1997) Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors, similarities and differences. Clin Pharmacokinet 32:403–425
87. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R (2007) Blood cholesterol and vascular mortality by age, sex, and blood pressure, a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370(9602):1829–1839
88. Lynen F (1997) The biochemical basis of the biosynthesis of cholesterol and fatty acids. Wien Klin Wochenschr 78:489–497
89. Maack C, Kartes T, Kilter H, Schäfers HJ, Nickenig G, Böhm M, Laufs U (2003) Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 108(13):1567–1574
90. Mahajan N, Bahl A, Dhawan V (2010) C-reactive protein (CRP) up-regulates expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: inhibitory effects of atorvastatin. Int J Cardiol 142:273–278
91. Mahajan N, Dhawan V (2010) In vitro modulation of peroxisome proliferator-activated receptor-g and its genes by C-reactive protein role of atorvastatin. Arch Med Res 41:154–161
92. Maki KC, Dicklin MR, Baum SJ (2015) Statins and diabetes. Cardiol Clin 33(2):233–243
93. Marzoll A, Melchior-Becker A, Cipollone F, Fischer JW (2011) Small leucine-rich proteoglycans in atherosclerotic lesions: novel targets of chronic statin treatment? J Cell Mol Med 15(2):232–243
94. Merhaut S, Trupp RJ (2010) Cardiorenal dysfunction AACN. Adv Crit Care 21(4):357–364
95. Mistafa O, Högberg J, Stenius U (2008) Statins and ATP regulate nuclear pAkt via the P2X7 purinergic receptor in epithelial cells. Biochem Biophys Res Commun 365(1):131–136
96. Morelli A, Chavalmane AK, Filippi S, Fibbi B, Silvestrini E, Sarchielli E, Zhang XH, Vignozzi L, Vannelli GB, Forti G (2009) Atorvastatin ameliorates sildenafil-induced penile erections in experimental diabetes by inhibiting diabetes-induced RhoA/Rho-kinase signaling hyperactivation. J Sex Med 6(1):91–106
97. Moroney JT, Tang M-X, Berglund L, Small S, Merchant C, Bell K, Stern Y, Mayeux R (1999) Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA 282(3):254–260
98. Muller C (1939) Angina pectoris in hereditary xanthomatosis. Arch Intern Med 64(4):675
99. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286(5446):1946–1949
100. Musiał J, Undas A, Gajewski P, et al. (2001) Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol 77:247–253
101. Nagashima T, Okazaki H, Yudoh K, Matsuno H, Minota S (2006) Apoptosis of rheumatoid synovial cells by statin s through the blocking of protein geranylgeranylation, a potential therapeutic approach to rheumatoid arthritis. Arthritis Rheum 54(2):579–586
102. Nakagawa H, Miki H, Ito M, Ohashi K, Takenawa T, Miyamoto S (2001) N-WASP, WAVE and Mena play different roles in the organization of actin cytoskeleton in lamellipodia. J Cell Sci 114(8):1555–1565
103. Nazzaro P, Manzari M, Merlo M, Triggiani R, Scarano A, Ciancio L, Pirrelli A (1999) Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Hypertension 33(2):719–725
104. Okumura T (1933) Hideyo Noguchi. Iwanami Shoten, Tokyo in Japanese
105. Okuyama H, Langsjoen PH, Hamazaki T, Ogushi Y, Hama R, Kobayashi T, Uchino H (2015) Statins stimulate atherosclerosis and heart failure, pharmacological mechanisms. Expert Rev Clin Pharmacol 8(2):189–199
106. Olivia Williams, Anne-Marie Jacks, Jim Davis, Sabrina Martinez (1998) Case 10, Merck(A), Mevacor. In Allan Afuah. Innovation Management—strategies, implementation, and profits. Oxford University Press ISBN 0-19-511346-2 Retrieved 2006-07-19
107. Oltman CL, Davidson EP, Coppey LJ, Kleinschmidt TL, Lund DD, Yorek MA (2008) Attenuation of vascular/neural dysfunction in Zucker rats treated with enalapril or rosuvastatin. Obesity 16(1):82–89
108. Palinski W, Tsimikas S (2002) Immunomodulatory effects of statin s, mechanisms and potential impact on arteriosclerosis. J Am Soc Nephrol 13(6):1673–1681
109. Pella D, Rybar R, Mechirova V (2005) Pleiotropic effects of statin s. Acta Card Sin 21(4):190
110. Peña JM, Aspberg S, MacFadyen J, Glynn RJ, Solomon DH, Ridker PM (2015) Statin therapy and risk of fracture results from the JUPITER randomized clinical trial. JAMA Intern Med 175(2):171–177
111. Perdices EV, Medina-Cáliz I, Hernando S, Ortega A, Martín-Ocaña F, Navarro JM, Peláez G, Castiella A, Hallal H, Romero-Gómez M, González-Jiménez A, Robles-Díaz M, Lucena MI, Andrade RJ (2014) Hepatotoxicity associated with statin use, analysis of the cases included in the Spanish Hepatotoxicity Registry. Rev EspEnferm Dig 106(4):246–254
112. Procino G, Barbieri C, Carmosino M, Tamma G, Milano S, De Benedictis L, Grazia Mola M, Lazo-Fernandez Y, Valenti G, Svelto M (2011) Fluvastatin modulates renal water reabsorption in vivo through increased AQP2 availability at the apical plasma membrane of collecting duct cells Pflugers. Arch Eur J Physiol 462:753–766
113. Racchi M, Baetta R, Salvietti N, Ianna P, Franceschini G, Paoletti R, Fumagalli R, Govoni S, Trabucchi M, Soma M (1997) Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content. Biochem J 322:893–896
114. Ramanjaneyulu SVVS, Trivedi PP, Kushwaha S, Vikram A, Jena GB (2013) Protective role of atorvastatin against doxorubicin-induced cardiotoxicity and testicular toxicity in mice. J Physiol Biochem 69(3):513–525
115. Rao SK, Prasad T, Mohanta GP, Manna PK (2011) An overview of statins as hypolipidemic drugs. Int J Pharm Sci Drug Res 3:178–183
116. Rattan S (2010) 3-Hydroxymethyl coenzyme A reductase inhibition attenuates spontaneous smooth muscle tone via RhoA/ROCK pathway regulated by RhoA prenylation. Am J Physiol-Gastr L 298(6):G962–G969
117. Ravnskov U, Rosch PJ, McCully KS (2015) Statins do not protect against cancer: quite the opposite. J Clin Oncol JCO-2014
118. Refolo LM, Pappolla MA, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K (2000) Hypercholesterolemia accelerates the Alzheimer’s amyloid pathology in a transgenic mouse model. Neurobiol Dis 7(4):321–331
119. Reinitzer F (1888) Contributions to the knowledge of cholesterol. Monatsh Chem 9:421–441
120. Reiss AB, Wirkowski E (2007) Role of HMG-CoA reductase inhibitors in neurological disorders. Drugs 67(15):2111–2120
121. Ridker PM (2003) Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein rationale and design of the JUPITER trial. Circulation 108(19):2292–2297
122. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347(20):1557–1565
123. Riento K, Ridley AJ (2003) Rocks, multifunctional kinases in cell behavior. Nat Rev Mol Cell Biol 4(6):446–456
124. Ross R (1999) Atherosclerosis—an inflammatory disease. N Engl J Med 340:115–125
125. Roth L, Rombouts M, Schrijvers DM, Martinet W, De Meyer GRY (2016) Cholesterol-independent effects of atorvastatin prevent cardiovascular morbidity and mortality in a mouse model of atherosclerotic plaque rupture. Vasc Pharmacol 16:S1537–S1891
126. Sarrabayrouse G, Synaeve C, Leveque K, Favre G, Tilkin-Manamé A-F (2007) Statins stimulate in vitro membrane FasL expression and lymphocyte apoptosis through RhoA/ROCK pathway in murine melanoma cells. Neoplasia 9(12):1078–1090
127. Sawada N, Liao JK (2014) Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statin s in atherosclerosis. Antioxid Redox Signal 20(8):1251–1267
128. Sawada N, Itoh H, Ueyama K, Yamashita J, Doi K, Chun T-H, Inoue M, Masatsugu K, Saito T, Fukunaga Y (2000) Inhibition of rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation 101(17):2030–2033
129. Senthil V, Chen SN, Tsybouleva N, Halder T, Nagueh SF, Willerson JT, Roberts R, Marian A (2005) Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ Res 97(3):285–292
130. Shao B-z, Han B-z, Zeng Y-x, Ding-feng S, Liu C (2016) The roles of macrophage autophagy in atherosclerosis. Acta Pharmacol Sin 37:150–156
131. Sharma I, Dhawan V, Mahajan N, Saha SC, Dhaliwal LK (2010) In vitro effects of atorvastatin on lipopolysaccharide-induced gene expression in endometriotic stromal cells. Fertil Steril 94(5):1639–46e1
132. Shavakhi A, Minakari M, Bighamian A, Sadeghian S, Shavakhi S, Khamisi N, Khodadustan M, Talebi M, Ataei B (2014) Statin efficacy in the treatment of hepatitis C genotype I. J Res Med Sci 1:S1–S4
133. Smaldone C, Brugaletta S, Pazzano V, Liuzzo G (2009) Immunomodulator activity of 3-hydroxy-3-methilglutaryl-CoA inhibitors. Cardiovasc Hematol Agents Med Chem 7(4):279–294
134. Sparks DL, Connor DJ, Sabbagh MN, Petersen RB, Lopez J, Browne P (2006) Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease, results of the Alzheimer’s Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol Scand 114(s185):3–7
135. Sposito AC, Carvalhz LS, Cintra RM, et al. (2009) Rebound inflammatory response during the acute phase of myocardial infarction after simvastatin withdrawal. Atherosclerosis 207:191–194
136. Stefanadis C, Toutouzas K, Vavuranakis M, et al. (2002) Statin treatment is associated with reduced thermal heterogeneity in human atherosclerotic plaques. Eur Heart J 23(21):1664–1669
137. Stone N J, Merz C N B, ScM F, Blum F C B, McBride F P, Eckel F R H, Schwartz F J S, Goldberg A C & Shero F S T (2013) ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol
138. Sun J, Yuan Y, Cai R, Sun H, Zhou Y, Wang P, Wang S (2015) An investigation into the therapeutic effects of statins with metformin on polycystic ovary syndrome: a meta-analysis of randomised controlled trials. BMJ Open 5(3):e007280
139. Sweetman Sean C, Ed (2009) Cardiovascular drugs: Martindale, the complete drug reference (36th ed) London. Pharmaceutical Press pp 1155–1434 ISBN 978-0-85369-840-1
140. Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y, Kitakaze M, Liao JK (2001) Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 108(10):1429–1437
141. Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK (2002) Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 106(1):57–62
142. Tanaka S-I, Fukumoto Y, Nochioka K, Minami T, Kudo S, Shiba N, Takai Y, Williams CL, Liao JK, Shimokawa H (2013) Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation. Arterioscler Thromb Vasc Biol 33(7):1591–1600
143. Taylor FC, Huffman M, Ebrahim S (2013) Statin therapy for primary prevention of cardiovascular disease. JAMA 310(22):2451–2452
144. Tomaszewski M, Karolina M, Joanna S, Tomaszewska S, Czuczwar J (2011) Statin -induced myopathies. Pharmacol Rep 63:859–866
145. Totoson P, Fhayli W, Faury G, Korichneva I, Cachot S, Baldazza M, Ribuot C, Pépin J-L, Lévy P, Joyeux-Faure M (2013) Atorvastatin protects against deleterious cardiovascular consequences induced by chronic intermittent hypoxia. Exp Biol Med 238(2):223–232
146. Tousoulis D, Oikonomou E, Economou EK, Crea F, Kaski JC (2016) Inflammatory cytokines in atherosclerosis: current therapeutic approaches. Eur Heart J:ehv759
147. Tsimikas S, Witztum JL, Miller ER, Sasiela WJ, Szarek M, Olsson AG, Schwartz GG (2004) High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 110(11):1406–1412
148. Uchiyama T, Atsuta H, Utsugi T, Ohyama Y, Nakamura T, Nakai A, Nakata M, Maruyama I, Tomura H, Okajima F (2006) Simvastatin induces heat shock factor 1 in vascular endothelial cells. Atherosclerosis 188(2):265–273
149. Undas A, Celinska-Lowenhoff M, Domagala TB, Iwaniec T, Dropinski J, Lowenhoff T, Szczeklik A (2005) Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia. Thromb Haemost 94(1):193–199
150. Vagelos PR (1991) Are prescription drug prices high? Science (New York, NY) 252(5009):1080–1084
151. Vagelos PR, Galambos L (2004) Medicine, Science and Merck. Cambridge University Press, Cambridge, pp. 1–301
152. Van de Ree M, Huisman M, Princen H, Meinders A, Kluft C (2003) Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 166(1):129–135
153. Vidal-Puig AJ, Considine RV, Jimenez-Liñan M, Werman A, Pories WJ, Caro JF, Flier JS (1997) Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 99(10):2416
154. Waters D, Schwartz GG, Olsson AG (2001) The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) trial, a new frontier for statins. Curr Control Trials Cardiovasc Med 2(3):111–114
155. Wassmann S, Laufs U, Bäumer AT, Müller K, Konkol C, Sauer H, Böhm M, Nickenig G (2001) Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells, involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 59(3):646–654
156. Wei Y-M, Li X, Xu M, Abais JM, Chen Y, Riebling CR, Boini KM, Li P-L, Zhang Y (2013) Enhancement of autophagy by simvastatin through inhibition of Rac1-mTOR signaling pathway in coronary arterial myocytes. Cell Physiol Biochem 31(6):925–937
157. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, Cottens S, Takada Y, Hommel U (2001) Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7(6):687–692
158. Welsh G, Hers I, Berwick D, Dell G, Wherlock M, Birkin R, Leney S, Tavare J (2005) Role of protein kinase B in insulin-regulated glucose uptake. Biochem Soc Trans 33(2):346–349
159. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57(10):1439–1443
160. Xiao H, Qin X, Ping D, Zuo K (2013) Inhibition of Rho and Rac geranylgeranylation by atorvastatin is critical for preservation of endothelial junction integrity. PLoS One 8(3):e59233
161. Xu H, Liu P, Liang L, Danesh FR, Yang X, Zhan YY, Z Yu X, Peng H, Sun L (2006) RhoA-mediated, tumor necrosis factor α–induced activation of NF-κB in rheumatoid synoviocytes: inhibitory effect of simvastatin. Arthritis Rheum 54(11):3441–3451
162. Yagi S, K-i A, Ikeda Y, Sumitomo Y, Yoshida S, Ise T, Iwase T, Ishikawa K, Azuma H, Akaike M (2008) Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II–induced cardiovascular remodeling and renal insufficiency. Circ Res 102(1):68–76
163. Yano M, Matsumura T, Senokuchi T, Ishii N, Murata Y, Taketa K, et al. (2007) Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ Res 100:1442–1451
164. Yavuz C, Demirtas S, Guclu O, Karahan O, Caliskan A, Yazici S, Mavitas B (2013) Rosuvastatin may have neuroprotective effect on spinal cord ischemia reperfusion injury. CNS Neurol Disord Drug Targets 12(7):1011–1016
165. Yiannopoulou KG, Papageorgiou SG (2013) Current and future treatments for Alzheimer’s disease. Ther Adv Neurol Disord 6(1):19–33
166. Zelvyte I, Dominaitiene R, Crisby M, Janciauskiene S (2002) Modulation of inflammatory mediators and PPAR γ and NFκβ expression by pravastatin in response to lipoproteins in human monocytes in-vitro. Pharmacol Res 45(2):147–154
167. Zhong W, Liang Y, Wang C, Chang T, Lee W (2005) Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling. Endocr Relat Cancer 12(3):615–629